
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Strontium-89 Chloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Q BioMed
Deal Size : Undisclosed
Deal Type : Agreement
Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada
Details : Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.
Product Name : Metastron
Product Type : Radiolabeled Compound
Upfront Cash : Undisclosed
August 10, 2021
Lead Product(s) : Strontium-89 Chloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Q BioMed
Deal Size : Undisclosed
Deal Type : Agreement
